Allergan, Inc.

Santen Pharmaceutical Co., Ltd.

Macusight, Inc.

Thierry Nivaggioli

David A Weber

Wendy M Blanda

Jane-Guo Shiah

Glenn T Huang

Lin Peng

Sreenivasu Mudumba

Rahul Bhagat

David Chou

Patrick Michael Hughes

Thomas C Malone

Lon T Spada

Joan-En Chang-Lin

Philippe J M Dor

Jeffrey L Edelman

Sidiq Farooq

Qing Lin

James Nienyuan Chang

Orest Olejnik

Hiroshi Sugimoto

David Maxwell Kleinman

Gerald Woodrow DeVries

Jane Guo Shiah

Gerald W De Vries

Mary E Gerritsen

Sudeep Kaur Takhar

James Jane-Guo Shiah

Jeffery L Edelman

Eugene Rex Cooper

Joan-En Lin

Philippe J Dor

Sidiq Mohammed Farooq

Philippe Jm Dor

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into the vitreous of an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants can be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Biodegradable intravitreal tyrosine kinase implants

Biodegradable implants sized and suitable for implantation in an ocular region or site and methods for treating ocular conditions. The implants provide an extended release of an active agent at a therapeutically effective amount for a period of time between 50 days and one year, or longer.

Extended release biodegradable ocular implants

The invention provides biodegradable implants sized for implantation in an ocular region and methods for treating medical conditions of the eye. The implants are formed from a mixture of hydrophilic end and hydrophobic end PLGA, and deliver active agents into an ocular region without a high burst release.

Ocular implant made by a double extrusion process

Described herein are formulations and methods for treating, inhibiting, preventing, delaying onset, or causing regression of a disease or condition relating to vascular permeability.

Formulations and methods for vascular permeability-related diseases or conditions

Described herein are liquid rapamycin formulations. Described herein are methods of treating or preventing diseases or conditions, such as choroidal neovascularization, wet AMD and dry AMD, and preventing transition of dry AMD to wet AMD, using the liquid rapamycin formulations described herein.

Rapamycin formulations and methods of their use

Described herein are liquid formulations which deliver a variety of therapeutic agents, including but not limited to rapamycin, to a subject for an extended period of time; liquid formulations which form a non-dispersed mass when placed in an aqueous medium of a subject; liquid formulations comprising a therapeutic agent and a plurality of polymers; and methods for delivering therapeutic agents to a subject for an extended period of time using the liquid formulations. The liquid formulation may be placed in an aqueous medium of a subject, including but not limited to via intraocular or periocular administration. A method may be used to administer rapamycin to treat or prevent angiogenesis, choroidal neovascularization, or age-related macular degeneration in a subject.

Liquid formulations for treatment of diseases or conditions

Biocompatible intraocular implants include a steroid and an auxiliary agent, where the auxiliary agent is present in an amount sufficient to lessen the severity of at least one side effect compared to the use of an otherwise identical implant lacking said auxiliary agent. The steroid and the auxiliary agent may be present on the same intraocular implant or on different implants. The steroid and auxiliary agent may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants containing the steroid and an auxiliary agent may be placed in an eye to treat one or more ocular conditions while reducing the side effects otherwise accompanying steroid use.

Steroid-containing sustained release intraocular implants and related methods

Biocompatible intraocular implants include a tyrosine kinase inhibitor and a biodegradable polymer that is effective to facilitate release of the tyrosine kinase inhibitor into an eye for an extended period of time. The therapeutic agents of the implants may be associated with a biodegradable polymer matrix, such as a matrix that is substantially free of a polyvinyl alcohol. The implants may be placed in an eye to treat or reduce the occurrence of one or more ocular conditions.

Sustained release intraocular implants containing tyrosine kinase inhibitors and related methods

Biocompatible intraocular implants include a steroid and a polymer associated with each other to facilitate release of the steroid into an eye for a period of time greater than about two months. The steroid may be associated with a biodegradable polymer matrix, such as a matrix of a two biodegradable polymers. Or, the steroid may be associated with a polymeric coating having one or more openings effective to permit the steroid to be released into an external environment. The implants may be placed in an eye to treat one or more ocular conditions. The steroid is released from the implant for more than about two months, and may be release for more than several years.

Sustained release intraocular implants and related methods

Growing community of inventors

Atherton, CA, United States of America

Thierry Nivaggioli